Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Phosphorus Disruption Is Associated with the Incidence and Severity of Neurotoxicity Symptoms in CD19-Targeted CAR-T Cell Therapy: A Pooled Clinical Trial Analysis

Penelope Lafeuille, Sheila Diamond, Alexandru Socolov, Jacob Aptekar, Theodore Nowicki

Blood (2023) 142 (Supplement 1): 3626.

https://doi.org/10.1182/blood-2023-182138

Published: 2023

Journal Articles

Machine Learning-Based Decision Tree for Identifying and Grading Severity of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Based on Neurological Adverse Events in Patients Treated with CD19 CAR-T

Alexandru Socolov, Penelope Lafeuille, Sheila Diamond, Eric Yang, Francesco Maura, Jacob Aptekar, Esther Nie

Blood (2023) 142 (Supplement 1): 5018.

https://doi.org/10.1182/blood-2023-182147

Published: 2023

Journal Articles

Significant Cytokine Release Syndrome Risk Model with T-Cell Engaging Therapies

Penelope Lafeuille, William Blumentals, Claire Brulle Wohlhueter, Weixi Chen, Chao Sang, Sydney Manning, Silvy Saltzman, Jan Canvin, Susan Richard, Cris Kamperschroer, Giovanni Abbadessa, Aniketh Talwai, Caroline Der-Nigoghossian, Yahav Itzkovich, Vibhu Agarwal, Rahul Jain, Tanmay Jain, Jacob Aptekar, Stephan Grupp

Blood (2023) 142 (Supplement 1): 3629.

https://doi.org/10.1182/blood-2023-181985

Published: 2023

Journal Articles

Immune Checkpoint Inhibitors and the Risk of Cardiovascular Adverse Events: A Pooled Clinical Trial Database Analysis

Kayleen Ports, Rahul Jain, Sheila Diamond, Jacob Aptekar, David C. Fajgenbaum

Blood (2023) 142 (Supplement 1): 6933.

https://doi.org/10.1182/blood-2023-181968

Published: 2023

Journal Articles

Deriving Predictive Features of Severe CRS from Pre-Infusion Clinical Data in CAR T-Cell Therapies

Vibhu Agarwal, Jacob Aptekar, David C Fajgenbaum, Penelope Lafeuille

Blood (2022) 140 (Supplement 1): 7838–7839.

https://doi.org/10.1182/blood-2022-169287

Published: 2022

Journal Articles

Patterns of Hematologic Function and Cytokine Release Syndrome Severity in ALL Patients Receiving CAR-T and TCR-T Therapies Using Pooled Clinical Trial Data

Vibhu Agarwal, Alexandru Socolov, Robert Buderi, Emelly Rusli, Lilia Bouzit, Aniketh Talwai, Yahav Itzkovich, Aaron Galaznik, Jacob Aptekar

Blood (2021) 138 (Supplement 1): 4826.

https://doi.org/10.1182/blood-2021-149180

Published: 2021

NARROW

Phosphorus Disruption Is Associated with the Incidence and Severity of Neurotoxicity Symptoms in CD19-Targeted CAR-T Cell Therapy: A Pooled Clinical Trial Analysis

Machine Learning-Based Decision Tree for Identifying and Grading Severity of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Based on Neurological Adverse Events in Patients Treated with CD19 CAR-T

Significant Cytokine Release Syndrome Risk Model with T-Cell Engaging Therapies

Immune Checkpoint Inhibitors and the Risk of Cardiovascular Adverse Events: A Pooled Clinical Trial Database Analysis

Deriving Predictive Features of Severe CRS from Pre-Infusion Clinical Data in CAR T-Cell Therapies

Patterns of Hematologic Function and Cytokine Release Syndrome Severity in ALL Patients Receiving CAR-T and TCR-T Therapies Using Pooled Clinical Trial Data

Email alerts

ASH Publications

American Society of Hematology

Phosphorus Disruption Is Associated with the Incidence and Severity of Neurotoxicity Symptoms in CD19-Targeted CAR-T Cell Therapy: A Pooled Clinical Trial Analysis

Machine Learning-Based Decision Tree for Identifying and Grading Severity of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Based on Neurological Adverse Events in Patients Treated with CD19 CAR-T

Significant Cytokine Release Syndrome Risk Model with T-Cell Engaging Therapies

Immune Checkpoint Inhibitors and the Risk of Cardiovascular Adverse Events: A Pooled Clinical Trial Database Analysis

Deriving Predictive Features of Severe CRS from Pre-Infusion Clinical Data in CAR T-Cell Therapies

Patterns of Hematologic Function and Cytokine Release Syndrome Severity in ALL Patients Receiving CAR-T and TCR-T Therapies Using Pooled Clinical Trial Data

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only